Retatrutide Half-Life: Why Once-Weekly Dosing Works

Retatrutide (LY-3437943) is Eli Lilly’s investigational GLP-1, GIP, and glucagon triple agonist. Search interest around retatrutide half-life is really a search for three related questions: how long the molecule stays in the body, why the trials dose it weekly, and how quickly exposure falls after the last dose. This page stays centered on those pharmacokinetic questions. For the regulatory answer, use the retatrutide approval tracker. For the week-by-week schedule, use the dosage guide.

What Is the Half-Life of Retatrutide?

The most useful answer from the published Lilly literature is: retatrutide has a half-life of approximately 6 days. That wording appears in the 2023 Lilly-authored research letter on gastric emptying, which states that retatrutide has a half-life of approximately 6 days supporting once-weekly dosing.^[1]

Earlier primary sources are directionally consistent even when they are less explicit. Lilly’s 2022 Cell Metabolism paper said the pharmacokinetic profile supported once-weekly dosing and that body-weight reduction persisted up to day 43 after a single dose.^[2] Lilly’s 2022 phase 1b Lancet trial reported dose-proportional pharmacokinetics and again said the half-life supports once-weekly dosing.^[3]

What Makes Retatrutide’s Half-Life Long?

The structural basis for the long half-life is lipidation. Retatrutide is engineered with a fatty diacid moiety that reversibly binds albumin in circulation. That albumin binding shields the molecule from rapid renal clearance and enzymatic breakdown, which is what gives it the roughly 6-day systemic profile rather than the hours-to-day timescale of unmodified peptides.^[2] Slow hepatic metabolism and the absence of cytochrome P450 involvement also reduce variability across patients. Peak plasma concentrations are typically reached within 12 to 72 hours after subcutaneous injection.

Mechanistically, retatrutide is a triple agonist at GLP-1, GIP, and glucagon receptors — that is the pharmacology piece, separate from how long the molecule stays in the body. Full receptor-by-receptor breakdown lives in the retatrutide research hub; the click-by-click dosing math sits in the calculator.

Why Does a 6-Day Half-Life Matter?

A 6-day half-life means the molecule clears slowly enough that weekly dosing makes pharmacokinetic sense. Concentrations do not crash between injections. Instead, each weekly dose overlaps with residual exposure from the previous one, which creates the smoother long-acting profile Lilly used across its obesity and diabetes trials.

It also explains why the escalation schedules are conservative. Long-acting exposure accumulates over time, so higher maintenance doses are reached in steps rather than all at once. In Lilly’s 2026 phase 3 diabetes release, participants started at 2 mg once weekly and moved upward every 4 weeks until reaching the target maintenance arm.^[5] The published obesity and diabetes programs use time as a tolerability tool.

How Long Does Retatrutide Stay in the System?

If retatrutide’s half-life is about 6 days, then clinically meaningful exposure can persist for several weeks after the last dose. A simple half-life estimate works like this: after one half-life about half the drug remains, after two half-lives about one-quarter remains, and after four to five half-lives only a small fraction is left. That puts rough washout in the 24-to-30-day range.

That timeline is an inference from half-life math, not a direct washout trial endpoint. Real biological effects do not switch off at one exact day. Appetite, gastric emptying, glycaemic effects, and weight trajectory can all fade on slightly different timelines.

Does Retatrutide Build Up With Weekly Dosing?

Yes. A long half-life means each weekly dose arrives before the previous dose has fully cleared. Over the first several weeks, exposure accumulates until a near-steady pattern is reached. That accumulation is normal for long-acting peptides and is part of why the dose-escalation blocks in retatrutide trials are measured in weeks, not days.

In practical terms, this means the effect of a dose change is not fully visible the next morning. There is carry-over from previous weeks. That is why protocol design, tolerability monitoring, and escalation pacing matter more for retatrutide than they would for a short-acting daily compound.

Half-Life vs Duration of Effect

Half-life tells you how fast concentration declines. It does not tell you, by itself, exactly how long the biological effect lasts. Lilly’s 2022 Cell Metabolism paper reported that body-weight reduction persisted through day 43 after a single dose in early-phase work.^[2] That does not mean the half-life is 43 days. It means the downstream pharmacodynamic effect outlasted the first week and remained measurable deep into the observation window.

The 2023 gastric-emptying paper adds another wrinkle: the authors noted that the time course of tachyphylaxis in gastric-emptying delay may be longer with retatrutide than with previously studied incretins.^[1] Plasma exposure, appetite effects, and GI effects are related, but they are not interchangeable clocks.

How the Long Half-Life Shapes Adverse Event Management

The dominant adverse events reported across the published trials are gastrointestinal — nausea, vomiting, diarrhea, abdominal discomfort — and they are dose-dependent, concentrated during the early dose-escalation phase. The long half-life is part of why escalation blocks are written in 4-week steps rather than days: with weekly dosing, exposure accumulates over the first several weeks, so each step-up is a change to a building plasma profile rather than a single isolated dose. Slow steps give the GI tract time to tolerate accumulating exposure.^[3] The conservative titration appears to pay off: the pivotal TRIUMPH-1 obesity readout (May 21, 2026) showed improved tolerability versus the earlier TRIUMPH-4 trial at the 12 mg dose — dysesthesia 12.5% vs 20.9% and AE-driven discontinuation 11.3% vs 18.2% — consistent with the cleaner obesity-only population and the optimised 2 mg start. The full per-event detail lives in the retatrutide side effects guide.

Trial readouts have not flagged significant cardiovascular or hepatic adverse events in non-diabetic populations, and hypoglycemia risk is low because the GLP-1 / GIP insulinotropic effects are glucose-dependent. The full per-event severity stratification, time-course, and management protocol live in the retatrutide side effects guide.

What Does Half-Life Mean for Titration and Missed-Dose Logic?

Long half-life is one reason retatrutide protocols are written around weekly intervals and gradual step-ups. In the published phase 3 diabetes program, participants began at 2 mg once weekly and moved upward every 4 weeks until reaching the assigned maintenance arm.^[5] The goal is not just efficacy. It is giving the body time to adapt while exposure accumulates.

The same principle applies to missed-dose interpretation: because concentrations decline gradually, retatrutide does not behave like a short-acting peptide that requires daily rescue logic. But the exact handling rule still depends on the specific published protocol. For exact weekly escalation paths and protocol-facing dose guidance, use the retatrutide dosage guide.

Is the Exact Half-Life Fully Settled in the Public Record?

Not perfectly. The most directly stated open-access figure is the approximately 6-day wording in Lilly’s 2023 DOM paper.^[1] Other primary sources are less numeric and simply describe the pharmacokinetic profile as supporting once-weekly dosing.^[2][3]

That is why the safest summary is conservative: retatrutide appears to be a roughly 6-day, once-weekly triple agonist. That wording is precise enough to be useful without pretending the public literature has given a more exact universal figure than it actually has.